

Corrigendum

Corrigendum to: Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis

Henri-Jean Aubin^{1,*}, Caroline Dureau-Pournin², Bruno Falissard³, François Paille⁴, Alain Rigaud⁵, Sophie Micon², Marine Pénichon², Frank Andersohn⁶, Christine Truchi^{7,†}, and Patrick Blin² on behalf of the USE-PACT study group[‡]

¹Université Paris-Saclay, Inserm, CESP, AP-HP. Université Paris Saclay, 12, avenue Paul-Vaillant-Couturier, 94804 Villejuif, France, ²Université de Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Rue Eugène Jacquet, Bordeaux 33000, France, ³CESP/INSERM U1018, Centre de Recherche en Epidémiologie et Santé des Populations, Hôpital Paul Brousse Bat 15/16, 16 av PV Couturier - 94807 Villejuif, France, ⁴Université de Lorraine, 34 Cours Léopold, 54000 Nancy, France, ⁵Ancien chef du pôle d'Addictologie de l'EPSM Marne, Psychiatre des hôpitaux honoraire, 28 bis, rue de Courcelles 51100 Reims, France, ⁶Frank Andersohn Consulting and Research Services, Mandelstrasse 16, 10409 Berlin, Germany, and ⁷Lundbeck SAS, 102 Terrasse Boieldieu 92085 Paris La Défense, France

*Corresponding author: Département de psychiatrie et d'addictologie, Pavillon Galilée—Secteur Jaune Porte 44, Hôpital Paul Brousse, 12, avenue Paul-Vaillant-Couturier, 94804 Villejuif Cedex, France. Tel.: (33) 145 59 39 51; Fax: (33) 145 59 35 68; E-mail: henri-jean.aubin@aphp.fr

Alcohol and Alcoholism, agab029, doi: [10.1093/alcalc/agab029](https://doi.org/10.1093/alcalc/agab029)

When this paper first published, it was missing the below conflict of interest statements from the authors. These conflict of interest statements now appear in the paper online.

Dr Patrick Blin wishes to record that he is an employee of the Bordeaux PharmacoEpi team in the University of Bordeaux, and the studies were performed by this team at the request of the French Health Technology Assessment agency, with a grant from Lundbeck and according to the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEEP) code of conduct and independence.

Dr François Paille wishes to record that he has received payments for consulting activity (Lundbeck, Indivior, D&A Pharma, and Kinnov therapeutics) and for invitations to speak at conferences connected with Lundbeck, Indivior and Pfizer.